4

Changes in Ownership

CRISPR Therapeutics AG Filed 2019-07-12 Acc 0000899243-19-019535

Chief Business Officer sold 20,000 shares at an average $50.02 ($1,000,353)

Chief Business Officer acquired 20,000 shares (option exercise)

From the SEC's structured data for this filing

Documents 1

4 Changes in Ownership , xslF345X03/doc4.xml

Around this filing

2019-08-05 4 Executive VP, Head of R&D gave up 14,534 shares (to pay taxes)
2019-07-12 4 Chief Business Officer sold 20,000 shares at an average $50.02 ($1,000,353)
2019-07-12 4 President sold 50,000 shares at $50.00 ($2,500,065)

Link to a passage

External

SEC EDGAR (opens in new tab)

Trades in this filing

Insider	Date	Transaction	Shares	Price	Value	Owned after	D/I
Klein Lawrence Otto Chief Business Officer	2019-07-10	Option exercise	+11,579	$5.86	$67,853	31,579	D
Klein Lawrence Otto Chief Business Officer	2019-07-10	Sale	−11,579	$50.02	$579,182	20,000	D
Klein Lawrence Otto Chief Business Officer	2019-07-11	Option exercise	+8,421	$5.86	$49,347	28,421	D
Klein Lawrence Otto Chief Business Officer	2019-07-11	Sale	−8,421	$50.01	$421,171	20,000	D
Derivatives
Klein Lawrence Otto Chief Business Officer	2019-07-10	Option exercise · Stock Option (Right to Buy)	−11,579			72,087	D
Klein Lawrence Otto Chief Business Officer	2019-07-11	Option exercise · Stock Option (Right to Buy)	−8,421			63,666	D
Open-market sales · 20,000 sh · avg $50.02 · $1,000,353